Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 102 от 222

Набира участници

Wearable Activity Tracking to Curb Hospitalizations

Hematopoietic Neoplasm Malignant Solid Neoplasm Lymphatic System Neoplasm

This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.

Начало: 07.04.2025 Край: 31.12.2027 Възраст: от 18 г.

United States University of California, San Francisco NCT06587100

Набира участници Фаза 4

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

Systemic Inflammation Immune Dysregulation Injection Drug Use HIV

This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.

Начало: 07.04.2025 Край: 30.11.2029 Възраст: 18–64 г.

United States University of Alabama at Birmingham NCT06829238

Набира участници

Listener Training for Improved Intelligibility of People With Parkinson's Disease

Dysarthria, Hypokinetic

Listener training offers a promising avenue for improving communication for people with dysarthria due to Parkinson's disease by offsetting the intelligibility burden from the patient onto their primary communication partners. Here, we employ a repeated-measures, randomized controlled trial to establish the efficacy of listener training for patients with PD and their primary communication partners. This translational work will establish a new realm of clinical practice in which the intelligibility impairments in PD are addressed by training partners to better understand dysarthric speech, thus elevating communication outcomes and participation in daily life.

Начало: 07.04.2025 Край: 01.05.2029 Възраст: от 18 г.

United States Utah State University NCT06815263

Набира участници

Emotional Intelligence Intervention to Improve Mental Well-Being of Adolescents With Emotional Distress (BEAM)

Emotional Distress

The goal of this clinical trial is to assess the effectiveness of a multicomponent intervention in adolescents with emotional distress. The main question it aims to answer is: Does the intervention increase mental well-being, emotional resilience, and emocional intelligence in adolescents with emotional distress? Participants will: • Participate in a multi-component intervention for 9 weeks at school.

Начало: 07.04.2025 Край: 30.12.2026 Възраст: 14–16 г.

Spain Consorci Sanitari de Terrassa NCT06713460

Набира участници

Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)

Transcatheter Aortic Valve Implantation (TAVI) Aortic Valve Stenosis Transcatheter Aortic Valve Replacement

The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device. The study will be conducted to evaluate the device design concept with respect to clinical safety and device functionality.

Начало: 07.04.2025 Край: 01.03.2026 Възраст: от 18 г. Устройства

Australia Transverse Medical, Inc. NCT06962371

Набира участници Фаза 1

A Phase I Study to Evaluate LIFE-001

Healthy Volunteers

The goal of this clinical trial is to learn if LIFE-001 is safe and tolerable for healthy adult volunteers.

Начало: 07.04.2025 Край: 13.11.2026 Възраст: 18–65 г. Лечение

Australia LifeMine Therapeutics NCT06904807

Набира участници Фаза 1

Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

This is a Phase 1, First-in-Human study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of PYC-003 in healthy adult participants and adult participants with confirmed PKD1 mutation-associated Autosomal Dominant Polycystic Kidney Disease (ADPKD) There are 3 parts in this study, i.e. Part A, Part B and Part C

Начало: 07.04.2025 Край: 01.03.2027 Възраст: 18–65 г. Лечение

Australia, New Zealand PYC Therapeutics NCT06714006

Набира участници Фаза 2

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Hyperkalemia

A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.

Начало: 06.04.2025 Край: 01.12.2030 Възраст: до 11 г. Лечение

Australia, Belgium, Finland +11 Vifor Pharma, Inc. NCT05766839

Набира участници Фаза 3

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on objective response rate (ORR) as assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors and to compare the effect of SG to SOC on overall survival (OS).

Начало: 04.04.2025 Край: 01.10.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +20 Gilead Sciences NCT06801834

Набира участници Фаза 1/2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast Cancer Advanced CCNE1-amplified Solid Tumors

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Начало: 03.04.2025 Край: 25.09.2028 Възраст: 18–100 г. Лечение

Australia, Canada, China +12 Novartis Pharmaceuticals NCT06726148

Набира участници

Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer Patients

Breast Cancer

The advances in early detection coupled with improvements in treatments have led to an ever-increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may represent valid additions to the currently available treatment options. Interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, improve survival and the quality of life. This is an observational, prospective study aimed at evaluating the effects of physical activity on the quality of life of patients with early stage hormone receptor positive breast cancer receiving adjuvant hormonal therapy and adhering to a physical activity program lasting for a total of 12 weeks organized by ANDOS onlus (Associazione Italiana Donne Operate al Seno).

Начало: 03.04.2025 Край: 31.12.2027 Възраст: от 18 г.

Italy Centro di Riferimento Oncologico - Aviano NCT07539038

Набира участници Ранна Фаза 1

Window of Opportunity Study of DSP-0390 in Gliomas

Glioma, Malignant IDH Mutation

This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will be drawn at various time points throughout the 2 weeks of treatment. The hypothesis is that DSP-0390 will accumulate in brain tumor tissue at pharmacologically relevant concentrations, and that alterations in cholesterol metabolism driven by mutant IDH will increase susceptibility to DSP-0390 and lead to tumor cell death.

Начало: 03.04.2025 Край: 17.05.2027 Възраст: от 18 г.

United States Washington University School of Medicine NCT06636162

Набира участници Фаза 1

A Phase 1 Study of S-4321

Healthy Volunteer

This is the first-in-human study of S-4321 designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers.

Начало: 03.04.2025 Край: 01.04.2026 Възраст: 18–65 г. Лечение

Australia Seismic Therapeutic AU Pty Ltd NCT06877611

Набира участници Фаза 1

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

Solid Tumours Advanced Solid Tumours

This is a multi-centre, two-part, open-label, phase 1, first in human study of multiple ascending doses of RC220 bisantrene formulation alone and in combination with fixed dose doxorubicin to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) in adult patients with advanced solid tumours where an anthracycline may be considered as a treatment option / or is indicated. The study will consist of Part 1 - dose-escalation, to determine the maximum tolerated combination dose of RC220 with doxorubicin to be evaluated in Part 2 - dose-expansion cohort, in patients with solid tumours that are anthracycline treatment naïve and for whom treatment with doxorubicin is indicated. The objective of Part 2 will be to confirm the safety and tolerability and evaluate the preliminary cardioprotective and anti-tumour efficacy of the maximum tolerated combined dose (MTCD) of RC220 with doxorubicin.

Начало: 02.04.2025 Край: 31.01.2029 Възраст: от 18 г. Лечение

Australia, Hong Kong Race Oncology Ltd NCT06815575

Набира участници

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

PreDiabetes

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Начало: 01.04.2025 Край: 01.07.2027 Възраст: 25–65 г.

United States Mayo Clinic NCT06424106

Набира участници Фаза 2

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

Corneal Transplant Failure

The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.

Начало: 01.04.2025 Край: 01.01.2031 Възраст: от 18 г.

United States Massachusetts Eye and Ear Infirmary NCT06753916

Набира участници

Telerehabilitation for Patients With Chronic Low Back Pain (TeleBACK Clinical Trial)

Chronic Low Back Pain

The investigators will conduct a prospective, randomized, clinical trial addressing key questions to understanding the effectiveness of telerehabilitation (physical therapy delivered via video-visits) and in-clinic physical therapy for patients with chronic low back pain (LBP). The investigators also seek to understand how patients engage with both care options and how these treatment options influence other LBP-related healthcare utilization. The investigators will explore implementation outcomes using a mixed methods approach consisting of electronic surveys and semi-structured interviews with patients, physical therapists, practice managers, and outpatient services administration focusing on perceived quality and impact on barriers to care. The investigators will enroll 1000 patients with chronic LBP seeking outpatient care at the healthcare systems in Maryland (Johns Hopkins Medicine (JHM)) and Utah (University of Utah (UU) and Intermountain Healthcare (IHC)). Eligible patients will provide informed consent and be randomized to receive telerehabilitation or in-clinic physical therapy delivered by a trained physical therapist. Primary effectiveness outcome is the difference in change in LBP-related disability (Oswestry Disability Index) after 8 weeks of treatment.

Начало: 01.04.2025 Край: 01.05.2030 Възраст: 18–64 г.

United States Johns Hopkins University NCT06821607

Набира участници

Randomized Trial of Tele Vs. Clinic TF-CBT in Puerto Rico

Post-Traumatic Stress Disorder

The current study will evaluate TF-CBT delivered via tele-health for youth presenting with trauma symptoms via a randomized controlled trial. Goals of the current study are to examine the effectiveness of Tele-TF-CBT delivered by community providers in Puerto Rico in improving youth trauma outcomes. Goals are also to support the feasibility, acceptability, and engagement outcomes of Tele-health delivery.

Начало: 01.04.2025 Край: 30.09.2026 Възраст: 7–18 г.

United States Medical University of South Carolina NCT06332209

Набира участници Фаза 3

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Lung Non-Small Cell Carcinoma Stage II Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

Начало: 01.04.2025 Край: 15.07.2039 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT06498635

Набира участници

Craniovertebral Angle and Fibromyalgia Severity

Craniovertebral Angle Fibromyalgia Syndrome

Forward Head Posture Frequency in Fibromyalgia Patients Assessed by Craniovertebral Angle: Association with Symptom Severity. Forward head posture is more common in patients with fibromyalgia and is a factor that increases symptom severity.

Начало: 01.04.2025 Край: 01.08.2026 Възраст: 18–55 г.

Turkey (Türkiye) Ankara Training and Research Hospital NCT06957873

1 … 100 101 102 103 104 … 222